Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission

NDA FilingIntelligent Fingerprinting Drug Screening SystemPositive

AI Analysis

Summary

Intelligent Bio Solutions announced above 98% accuracy results from a multi-site clinical study of its Intelligent Fingerprinting Drug Screening System, supporting a planned 2026 FDA 510(k) submission.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Multi-site clinical study achieved above 98% accuracy in method comparison study

Importance:6/10

Sentiment:

0.75

clinical data510(k) submissiondrug screeningFDA regulatorymethod comparison

Related Companies

$INBS

Read the original article

Published by GlobeNewswire Clinical Studies on September 1, 2026 12:31 PM

Read Original